July 2026
PTSD
What July 2026's 10 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research published in July 2026 on PTSD focused heavily on psychedelic-assisted therapies, with MDMA-assisted therapy showing promise in reducing PTSD symptoms, including discrimination-related trauma, though evidence is preliminary and often based on small samples. Psilocybin and ketamine also showed potential benefits, but findings were mixed regarding neural effects and the role of support. Other studies highlighted the importance of dissociation, nightmares, and mindfulness processes in PTSD, but overall conclusions are limited by small sample sizes, lack of long-term follow-up, and the need for larger trials.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder 2026 | RCT | 22 | Unclear | During psilocybin administration sessions, 78% of time was filled with silence, and support was minimally enacted but experientially salient, suggesting that non-directive support may be important. |
| Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder 2026 | review | Supports | Psychedelic therapies, particularly MDMA-assisted therapy, show potential as a breakthrough by targeting underlying causes of PTSD, with MDMA-assisted therapy showing 67% of participants no longer meeting PTSD criteria at endpoint. | |
| Mindfulness Processes and User Experiences in a Randomized Controlled Trial of the Mindfulness Coach App for Veterans with Posttraumatic Stress Disorder 2026 | RCT | 173 | Supports | The Mindfulness Coach app produced significant between-group improvements in two mindfulness facets (describing and nonjudgment) among completers, and qualitative data suggested perceived mental health benefits. |
| Changes in trauma symptoms of discrimination after MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026 | preliminary study | 5 | Supports | MDMA-assisted therapy significantly reduced discrimination-related trauma symptoms, with a 38% decrease in TSDS scores and a large effect size (Cohen's d = 1.28). |
| Temporal associations between nightmares and PTSD symptoms in the acute post-sexual assault period: An ecological momentary assessment study 2026 | observational cohort | 54 | Mixed | Within-person associations between nightmares and PTSD symptoms were not significant after adjusting for autoregressive effects, but between-person associations showed that individuals with frequent nightmares had higher PTSD symptoms. |
| Dissociation and PTSD in women with a history of childhood sexual abuse: a pilot examination of a specialized inpatient unit 2026 | pilot study | 108 | Supports | Dissociative symptoms, especially maladaptive absorption, were positively correlated with PTSD severity, and reductions in absorption were associated with PTSD improvement after treatment. |
| Ketamine effects on EEG and their links to therapy differ across treatment-resistant major depression, post-traumatic stress disorder, and obsessive-compulsive disorder 2026 | experimental, within-subjects, placebo-controlled | 42 | Mixed | Ketamine's EEG effects and their correlation with symptom improvement differ by band, electrode, and diagnosis, with TR-PTSD showing dose-dependent alpha changes and TR-MDD showing none. |
| Retreat from Racism: A Psychedelic Group Experience for Racial Stress and Trauma 2026 | prospective naturalistic observational study | 11 | Supports | The retreat model was feasible and functioned as a culturally responsive container, with the absence of systemic racial threats and communal witnessing acting as active therapeutic agents. |
| Making a case for using MDMA-assisted psychotherapy for borderline personality disorder and complex PTSD: a descriptive systematic review of the literature 2026 | descriptive systematic review | 335 | Supports | MDMA-assisted psychotherapy may have applicability beyond PTSD, with potential benefits for complex PTSD and borderline personality disorder, though no studies directly assessed these conditions. |
| MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder 2026 | RCT | 100 | Unclear | The trial will test whether MDMA-assisted integrated exposure therapy improves PTSD and alcohol use outcomes compared to active control-assisted integrated exposure therapy in comorbid PTSD and AUD. |
During psilocybin administration sessions, 78% of time was filled with silence, and support was minimally enacted but experientially salient, suggesting that non-directive support may be important.
RCT Sample size: 22
Psychedelic therapies, particularly MDMA-assisted therapy, show potential as a breakthrough by targeting underlying causes of PTSD, with MDMA-assisted therapy showing 67% of participants no longer meeting PTSD criteria at endpoint.
review
The Mindfulness Coach app produced significant between-group improvements in two mindfulness facets (describing and nonjudgment) among completers, and qualitative data suggested perceived mental health benefits.
RCT Sample size: 173
MDMA-assisted therapy significantly reduced discrimination-related trauma symptoms, with a 38% decrease in TSDS scores and a large effect size (Cohen's d = 1.28).
preliminary study Sample size: 5
Within-person associations between nightmares and PTSD symptoms were not significant after adjusting for autoregressive effects, but between-person associations showed that individuals with frequent nightmares had higher PTSD symptoms.
observational cohort Sample size: 54
Dissociative symptoms, especially maladaptive absorption, were positively correlated with PTSD severity, and reductions in absorption were associated with PTSD improvement after treatment.
pilot study Sample size: 108
Ketamine's EEG effects and their correlation with symptom improvement differ by band, electrode, and diagnosis, with TR-PTSD showing dose-dependent alpha changes and TR-MDD showing none.
experimental, within-subjects, placebo-controlled Sample size: 42
The retreat model was feasible and functioned as a culturally responsive container, with the absence of systemic racial threats and communal witnessing acting as active therapeutic agents.
prospective naturalistic observational study Sample size: 11
MDMA-assisted psychotherapy may have applicability beyond PTSD, with potential benefits for complex PTSD and borderline personality disorder, though no studies directly assessed these conditions.
descriptive systematic review Sample size: 335
The trial will test whether MDMA-assisted integrated exposure therapy improves PTSD and alcohol use outcomes compared to active control-assisted integrated exposure therapy in comorbid PTSD and AUD.
RCT Sample size: 100
Points of agreement
- Psychedelic-assisted therapies, particularly MDMA, show promise in reducing PTSD symptoms across various populations.
- Psilocybin and ketamine also show potential benefits for PTSD, though effects may vary by diagnosis.
- Support and context are important in psychedelic therapy, with non-directive support and culturally responsive settings being highlighted.
Conflicts
- Ketamine's neural effects differ across diagnoses, with TR-PTSD showing dose-dependent alpha changes while TR-MDD shows none.
- Within-person associations between nightmares and PTSD symptoms were not significant after adjusting for autoregressive effects, contrasting with between-person associations.
Gaps
- Long-term durability of treatment effects is not addressed in most studies.
- Sample sizes are often small, limiting generalizability.
- Blinding and control conditions are not always robust, especially in psychedelic trials.
- Specific populations such as those with comorbid conditions or diverse backgrounds are underrepresented.
- Dose-response relationships and optimal dosing regimens require further investigation.